|
1
|
Eisenkop SM, Friedman RL and Wang HJ:
Complete cytoreductive surgery is feasible and maximizes survival
in patients with advanced epithelial ovarian cancer: a prospective
study. Gynecol Oncol. 69:103–108. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chi DS, Franklin CC, Levine DA, et al:
Improved optimal cytoreduction rates for stages IIIC and IV
epithelial ovarian, fallopian tube, and primary peritoneal cancer:
a change in surgical approach. Gynecol Oncol. 94:650–654. 2004.
View Article : Google Scholar
|
|
3
|
Chi DS, McCaughty K, Diaz JP, et al:
Guidelines and selection criteria for secondary cytoreductive
surgery in patients with recurrent, platinum-sensitive epithelial
ovarian carcinoma. Cancer. 106:1933–1939. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harter P, du Bois A, Hahmann M, et al;
Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee;
AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian
cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO)
DESKTOP OVAR trial. Ann Surg Oncol. 13:1702–1710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shih KK and Chi DS: Maximal cytoreductive
effort in epithelial ovarian cancer surgery. J Gynecol Oncol.
21:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Berek JS, Hacker NF, Lagasse LD, Nieberg
RK and Elashoff RM: Survival of patients following secondary
cytoreductive surgery in ovarian cancer. Obstet Gynecol.
61:189–193. 1983.PubMed/NCBI
|
|
7
|
Munkarah AR and Coleman RL: Critical
evaluation of secondary cytoreduction in recurrent ovarian cancer.
Gynecol Oncol. 95:273–280. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eisenkop SM, Friedman RL and Spirtos NM:
The role of secondary cytoreductive surgery in the treatment of
patients with recurrent epithelial ovarian carcinoma. Cancer.
88:144–153. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harter P, Sehouli J, Reuss A, et al:
Prospective validation study of a predictive score for operability
of recurrent ovarian cancer: the Multicenter Intergroup Study
DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group,
NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 21:289–295.
2011. View Article : Google Scholar
|
|
10
|
Leitao MM Jr, Kardos S, Barakat RR and Chi
DS: Tertiary cytoreduction in patients with recurrent ovarian
carcinoma. Gynecol Oncol. 95:181–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shih KK, Chi DS, Barakat RR and Leitao MM
Jr: Tertiary cytoreduction in patients with recurrent epithelial
ovarian, fallopian tube, or primary peritoneal cancer: an updated
series. Gynecol Oncol. 117:330–335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fotopoulou C, Richter R, Braicu IE, et al:
Clinical outcome of tertiary surgical cytoreduction in patients
with recurrent epithelial ovarian cancer. Ann Surg Oncol. 18:49–57.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Karam AK, Santillan A, Bristow RE, et al:
Tertiary cytoreductive surgery in recurrent ovarian cancer:
selection criteria and survival outcome. Gynecol Oncol.
104:377–380. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gultekin M, Velipaşaoǧlu M, Aksan G, et
al: A third evaluation of tertiary cytoreduction. J Surg Oncol.
98:530–534. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shih KK, Chi DS, Barakat RR and Leitao MM
Jr: Beyond tertiary cytoreduction in patients with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol. 116:364–369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fotopoulou C, Savvatis K, Kosian P, et al:
Quaternary cytoreductive surgery in ovarian cancer: does surgical
effort still matter? Br J Cancer. 108:32–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hizli D, Boran N, Yilmaz S, et al: Best
predictors of survival outcome after tertiary cytoreduction in
patients with recurrent platinum-sensitive epithelial ovarian
cancer. Eur J Obstet Gynecol Reprod Biol. 163:71–75. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fotopoulou C, Zang R, Gultekin M, et al:
Value of tertiary cytoreductive surgery in epithelial ovarian
cancer: an international multicenter evaluation. Ann Surg Oncol.
20:1348–1354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gordon AN, Fleagle JT, Guthrie D, Parkin
DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma:
a randomized phase III study of pegylated liposomal doxorubicin
versus topotecan. J Clin Oncol. 19:3312–3322. 2001.PubMed/NCBI
|
|
20
|
Mutch DG, Orlando M, Goss T, Teneriello
MG, et al: Randomized phase III trial of gemcitabine compared with
pegylated liposomal doxorubicin in patients with platinum-resistant
ovarian cancer. J Clin Oncol. 25:2811–2818. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fotopoulou C, Richter R, Braicu IE, et al:
Clinical outcome of tertiary surgical cytoreduction in patients
with recurrent epithelial ovarian cancer. Ann Surg Oncol. 18:49–57.
2011. View Article : Google Scholar : PubMed/NCBI
|
